---
document_datetime: 2025-06-17 12:07:03
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/xevudy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: xevudy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.2138211
conversion_datetime: 2025-12-26 09:55:02.999078
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Xevudy

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | B.II.f.1.b Extension of the shelf life of the | 16/06/2025                          |                                             | SmPC,                            |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000269654   | finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted   | Labelling and PL   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|